PTGX vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Momentum & Technical, Options & Structure while PTGX counters with relative strength in Growth & Margin. Fundamentally, PTGX trades at 36.9x Forward P/E with 58.6% operating margin (+5723.6% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, PTGX sits in CONSOLIDATION (16th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PTGX | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $8.1B | $2.1B | Larger Scale | PTGX |
| Trailing P/E Ratio Valuation | 26.2x | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 36.9x | 28.8x | Lower Multiple | AVDL |
| Revenue Growth (YoY) Growth | +5723.6% | +54.9% | Higher Growth | PTGX |
| Operating Margin (TTM) Profitability | 58.6% | 2.5% | Higher Margin | PTGX |
| Net Profit Margin Profitability | 62.0% | -0.1% | Higher Margin | PTGX |
| Return on Equity (ROE) Capital Efficiency | 39.6% | -0.3% | Higher ROE | PTGX |
| 52-Week Range Position Momentum | 53% ($77โ$161) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.97ฮฒ ยท 36% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 44.6 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AVDL |